MabThera/Rituxan revenue trends
Roche’s (RHHBY) MabThera/Rituxan reported revenues of 3.45 billion Swiss francs in the first half compared to 3.8 billion Swiss francs in the first half of 2017, which reflected ~9.0% YoY (year-over-year) decline at CER (constant exchange rates).
In the United States, Europe, and Japan, MabThera/Rituxan generated first-half revenues of 2.1 billion Swiss francs, 525.0 million Swiss francs, and 105.0 million Swiss francs, respectively, which reflected ~3.0% growth, ~47.0% decline, and 23.0% decline on a YoY basis at CER.
The launch of biosimilar versions of MabThera in most of the member countries of the European Union led to the decline of MabThera’s revenues in the European markets.
In the first half, in the international markets (markets outside the United States, Europe, and Japan), MabThera/Rituxan reported revenues of 697.0 million Swiss francs, reflecting ~7.0% YoY growth at CER. The sales growth in the Chinese market primarily drove MabThera/Rituxan’s international market’s revenues.
In the second quarter, MabThera/Rituxan reported revenues of 1.7 billion Swiss francs, which reflected an ~11.0% YoY decline at CER.
Rituxan/MabThera is used to treat CLL (chronic lymphocytic leukemia), non-Hodgkin lymphoma, follicular lymphoma, rheumatoid arthritis, and certain kinds of antineutrophil cytoplasmic antibody related to vasculitis.
Among Rituxan’s peers in the CLL drugs market, Johnson & Johnson’s (JNJ) Imbruvica and Gilead Sciences’ (GILD) Zydelig generated revenues of $620.0 million and $39.0 million, respectively, in the second quarter.
Gazyva’s revenue trends
Gazyva reported revenues of 177.0 million Swiss francs in the first half compared to 133.0 million in the first half of 2017, which reflected ~32.0% YoY growth at CER. In the first half in the United States and European markets, Gazyva generated revenues of 93.0 million Swiss francs and 63.0 million Swiss francs, respectively, reflecting ~23.0% and 65.0% YoY growth at CER.
In the second quarter, Gazyva reported revenues of 93.0 million, which reflected ~38.0% YoY growth at CER. In the second quarter in the United States and European markets, Gazvya reported revenues of 50.0 million Swiss francs and 34.0 million Swiss francs, respectively.
In June, Roche presented data of the final analysis of the CLL11 trial of Gazyva at the Presidential Symposium at the 23rd European Hematology Association (or EHA) Annual Congress. The five-year follow-up analysis of the trial showed that Gazyva and chlorambucil combination therapy had clinically meaningful progression across multiple endpoints.
These endpoints include progression in PFS (progression-free survival) and overall survival (or OS) compared to Rituxan and chlorambucil combination therapy in previously untreated individuals with chronic lymphoblastic leukemia.
To learn more in detail about the clinical trial results, please refer to Roche’s press release.